Condition
Ann Arbor Stage I Mantle Cell Lymphoma
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Active Not Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT02494700Phase 2Active Not Recruiting
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
NCT02489123Phase 2TerminatedPrimary
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Showing all 2 trials